Growing evidence suggests that microRNAs are involved in the development and progression of colorectal cancer (CRC). In the present study, deregulation and functioning of tumor-suppressive miR-215-5p was evaluated in CRC. In total, 448 tumor tissues and 325 paired adjacent healthy tissues collected from Czech and Spain cohorts of CRC patients have been used for miR-215-5p expression analyses. A series of in vitro experiments have been performed using transient transfection of miR-215-5p mimics into four CRC cell lines to identify specific cellular processes affected by miR-215-5p. Further, the effects of miR-215-5p on tumor growth were evaluated in vivo using NSG mice and stable cell line overexpressing miR-215-5p. Target mRNAs of miR-215-5p were tested using luciferase assay and western blot analyses. We found that miR-215-5p is significantly downregulated in tumor tissues compared with non-tumor adjacent tissues and its decreased levels correlate with the presence of lymph node metastases, tumor stage, and shorter overall survival in CRC patients. Overexpression of miR-215-5p significantly reduced proliferation, clonogenicity, and migration of CRC cells, lead to cell cycle arrest in G2/M phase and p53-dependent induction of apoptosis. The ability of miR-215-5p to inhibit tumor growth was confirmed in vivo. Finally, we confirmed epiregulin and HOXB9 to be the direct targets of miR-215-5p. As epiregulin is EGFR ligand and HOXB9 is its transcriptional inducer, we suggest that the main molecular link between miR-215-5p and CRC cells phenotypes presents the EGFR signaling pathway, which is one of the canonical pathogenic pathways in CRC.

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Clinical Analysis Santa Lucia University Hospital Cartagena Spain

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Faculty of Medicine Masaryk University Brno Czech Republic

Department of Pathology Santa Lucia University Hospital Cartagena Spain

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. PubMed DOI

Sana J, Faltejskova P, Svoboda M, Slaby O. Novel classes of non-coding RNAs and cancer. J. Transl. Med. 2012;10:103. doi: 10.1186/1479-5876-10-103. PubMed DOI PMC

Gomes AQ, Nolasco S, Soares H. Non-coding RNAs: multi-tasking molecules in the cell. Int. J. Mol. Sci. 2013;14:16010–16039. doi: 10.3390/ijms140816010. PubMed DOI PMC

Crea F, Clermont PL, Parolia A, Wang Y, Helgason CD. The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer Metastasis Rev. 2014;33:1–16. doi: 10.1007/s10555-013-9455-3. PubMed DOI PMC

Joh RI, Palmieri CM, Hill IT, Motamedi M. Regulation of histone methylation by noncoding RNAs. Biochim. Biophys. Acta. 2014;1839:1385–1394. doi: 10.1016/j.bbagrm.2014.06.006. PubMed DOI PMC

Lai EC. Micro RNAs are complementary to 3’ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet. 2002;30:363–364. doi: 10.1038/ng865. PubMed DOI

Cho WCS. OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer. 2007;6:60. doi: 10.1186/1476-4598-6-60. PubMed DOI PMC

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer. 2006;6:857–866. doi: 10.1038/nrc1997. PubMed DOI

Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol. Cancer. 2009;8:102. doi: 10.1186/1476-4598-8-102. PubMed DOI PMC

Amankwatia EB, et al. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br. J. Cancer. 2015;112:1480–1490. doi: 10.1038/bjc.2015.125. PubMed DOI PMC

Faltejskova P, et al. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J. Cell. Mol. Med. 2012;16:2655–2666. doi: 10.1111/j.1582-4934.2012.01579.x. PubMed DOI PMC

Necela BM, Carr JM, Asmann YW, Thompson EA. Differential expression of microRNAs in tumors from chronically inflamed or genetic (APC(Min/ + )) models of colon cancer. PLoS ONE. 2011;6:e18501. doi: 10.1371/journal.pone.0018501. PubMed DOI PMC

Braun CJ, et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 2008;68:10094–10104. doi: 10.1158/0008-5472.CAN-08-1569. PubMed DOI PMC

Song B, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol. Cancer. 2010;9:96. doi: 10.1186/1476-4598-9-96. PubMed DOI PMC

Boni V, et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol. Cancer Ther. 2010;9:2265–2275. doi: 10.1158/1535-7163.MCT-10-0061. PubMed DOI

Li S, et al. MicroRNA-215 inhibits relapse of colorectal cancer patients following radical surgery. Med. Oncol. Northwood Lond. Engl. 2013;30:549. doi: 10.1007/s12032-013-0549-0. PubMed DOI

Agarwal, V., Bell G. W., Nam J.-W. & Bartel, D.P. Predicting effective microRNA target sites in mammalian mRNAs. eLife4, e05005 (2015). PubMed PMC

Maragkakis M, et al. DIANA-microT Web server upgrade supports Fly and Worm miRNA target prediction and bibliographic miRNA to disease association. Nucleic Acids Res. 2011;39:W145–W148. doi: 10.1093/nar/gkr294. PubMed DOI PMC

Rehmsmeier M, Steffen P, Höchsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA. 2004;10:1507–1517. doi: 10.1261/rna.5248604. PubMed DOI PMC

Miranda KC, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006;126:1203–1217. doi: 10.1016/j.cell.2006.07.031. PubMed DOI

John B, et al. Human microRNA targets. PLoS Biol. 2004;2:e363. doi: 10.1371/journal.pbio.0020363. PubMed DOI PMC

Riese DJ, Cullum RL. Epiregulin: roles in normal physiology and cancer. Semin. Cell Dev. Biol. 2014;28:49–56. doi: 10.1016/j.semcdb.2014.03.005. PubMed DOI PMC

Zhan J, et al. Elevated HOXB9 expression promotes differentiation and predicts a favourable outcome in colon adenocarcinoma patients. Br. J. Cancer. 2014;11:883–893. doi: 10.1038/bjc.2014.387. PubMed DOI PMC

Bonfrate L, et al. MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment. J. Gastrointest. Liver Dis. 2013;22:311–320. PubMed

Hollis M, et al. MicroRNAs potential utility in colon cancer: early detection, prognosis, and chemosensitivity. World J. Gastroenterol. 2015;21:8284–8292. doi: 10.3748/wjg.v21.i27.8284. PubMed DOI PMC

Stiegelbauer V, et al. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J. Gastroenterol. 2014;20:11727–11735. doi: 10.3748/wjg.v20.i33.11727. PubMed DOI PMC

Karaayvaz M, et al. Prognostic significance of miR-215 in colon cancer. Clin. Colorectal. Cancer. 2011;10:340–347. doi: 10.1016/j.clcc.2011.06.002. PubMed DOI PMC

Slattery ML, et al. An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int. J. Cancer. 2015;137:428–438. doi: 10.1002/ijc.29384. PubMed DOI PMC

Zhang JX, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013;14:1295–1306. doi: 10.1016/S1470-2045(13)70491-1. PubMed DOI

Yang J, et al. Expression analysis of microRNA as prognostic biomarkers in colorectal cancer. Oncotarget. 2017;8:52403–52412. PubMed PMC

Georges SA, et al. Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res. 2008;68:10105–10112. doi: 10.1158/0008-5472.CAN-08-1846. PubMed DOI

Banks D, et al. L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle (Georgetown, TX) 2006;5:1719–1729. doi: 10.4161/cc.5.15.3150. PubMed DOI

Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008;27:6920–6929. doi: 10.1038/onc.2008.343. PubMed DOI PMC

Nechiporuk T, Fernandez TE, Vasioukhin V. Failure of epithelial tube maintenance causes hydrocephalus and renal cysts in Dlg5-/- mice. Dev. Cell. 2007;13:338–350. doi: 10.1016/j.devcel.2007.07.017. PubMed DOI PMC

Ge G, et al. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis. Oncol. Rep. 2016;35:1816–1822. doi: 10.3892/or.2015.4482. PubMed DOI

Ye M, et al. Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. Cancer Lett. 2015;357:196–205. doi: 10.1016/j.canlet.2014.11.028. PubMed DOI

White NMA, et al. mRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br. J. Cancer. 2011;105:1741–1749. doi: 10.1038/bjc.2011.401. PubMed DOI PMC

Hou Y, et al. miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer. Oncol. Lett. 2015;10:1985–1992. doi: 10.3892/ol.2015.3587. PubMed DOI PMC

Li QW, et al. MicroRNA-215 functions as a tumor suppressor and directly targets ZEB2 in human pancreatic cancer. Genet. Mol. Res. 2015;14:16133–16145. doi: 10.4238/2015.December.8.2. PubMed DOI

Huang K, et al. Overexpression of HOXB9 promotes metastasis and indicates poor prognosis in colon cancer. Chin. J. Cancer Res. 2014;26:72–80. PubMed PMC

Shrestha B, et al. Homeodomain containing protein HOXB9 regulates expression of growth and angiogenic factors, facilitates tumor growth in vitro and is overexpressed in breast cancer tissue. FEBS J. 2012;279:3715–3726. doi: 10.1111/j.1742-4658.2012.08733.x. PubMed DOI PMC

Hayashida T, et al. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc. Natl. Acad. Sci. USA. 2010;107:1100–1105. doi: 10.1073/pnas.0912710107. PubMed DOI PMC

Wu SY, et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat. Commun. 2016;7:11169. doi: 10.1038/ncomms11169. PubMed DOI PMC

Song B, et al. miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53 microRNA circuit. Clin. Cancer Res. 2008;14:8080–8086. doi: 10.1158/1078-0432.CCR-08-1422. PubMed DOI PMC

Bunz F, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282:1497–1501. doi: 10.1126/science.282.5393.1497. PubMed DOI

Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat. Protoc. 2007;2:247–250. doi: 10.1038/nprot.2007.25. PubMed DOI

McKay JA, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur. J. Cancer. 2002;38:2258–2264. doi: 10.1016/S0959-8049(02)00234-4. PubMed DOI

Harnessing p53 for targeted cancer therapy: new advances and future directions

Barriers in systemic delivery and preclinical testing of synthetic microRNAs in animal models: an experimental study on miR-215-5p mimic

MiR-215-5p Reduces Liver Metastasis in an Experimental Model of Colorectal Cancer through Regulation of ECM-Receptor Interactions and Focal Adhesion

MicroRNA Biogenesis Pathway Genes Are Deregulated in Colorectal Cancer